Orchard Therapeutics says GSK’s cell line tech will reduce reliance on plasmids and speed gene therapy development. The UK gene therapy firm licensed GSK’s lentiviral stable cell line technology (LV-SCLT) this week. The plan is to use the cell line to produce OTL-103 – a candidate for Wiskott Aldrich syndrome – and OTL-300 – a therapy for transfusion-dependent beta thalassemia. Orchard spokeswoman Molly Cameron told Bioprocess Insider “We aren’t disclosing financial details around the deal, however this agreement aligns with…